Salirasib is a salicylic acid derivative with potential antineoplastic activity. Salirasib dislodges all Ras isoforms from their membrane-anchoring sites, thereby preventing activation of RAS signaling cascades that mediated cell proliferation, differentiation, and senescence. RAS signaling is believed to be abnormally activated in one-third of human cancers, including cancers of the pancreas, colon, lung and breast.
Ras Inhibitors Related Products:
Lonafarnib; Kobe2602; Zoledronic acid; K-Ras-IN-1; Zoledronic acid hydrate; Kobe0065; Deltarasin; K-Ras(G12C) inhibitor; Adagrasib